You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

EC approves BMS’ Opdivo as adjuvant treatment for oesophageal or GEJ cancer patients

Bristol Myers Squibb (BMS) has announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with oesophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).